nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CYP2D6—Fingolimod—multiple sclerosis	0.136	0.261	CbGbCtD
Cevimeline—CYP3A4—Fingolimod—multiple sclerosis	0.0867	0.166	CbGbCtD
Cevimeline—CYP3A4—Methylprednisolone—multiple sclerosis	0.0559	0.107	CbGbCtD
Cevimeline—CYP3A4—Triamcinolone—multiple sclerosis	0.0423	0.081	CbGbCtD
Cevimeline—CYP3A4—Mitoxantrone—multiple sclerosis	0.0408	0.078	CbGbCtD
Cevimeline—CYP3A4—Betamethasone—multiple sclerosis	0.0363	0.0695	CbGbCtD
Cevimeline—CYP3A4—Prednisolone—multiple sclerosis	0.0358	0.0686	CbGbCtD
Cevimeline—CYP3A4—Prednisone—multiple sclerosis	0.0338	0.0648	CbGbCtD
Cevimeline—CYP2D6—Dexamethasone—multiple sclerosis	0.0332	0.0636	CbGbCtD
Cevimeline—CYP3A4—Dexamethasone—multiple sclerosis	0.0211	0.0404	CbGbCtD
Cevimeline—Vertigo—Dexamethasone—multiple sclerosis	0.000221	0.000484	CcSEcCtD
Cevimeline—Syncope—Betamethasone—multiple sclerosis	0.00022	0.000483	CcSEcCtD
Cevimeline—Syncope—Dexamethasone—multiple sclerosis	0.00022	0.000483	CcSEcCtD
Cevimeline—Arrhythmia—Prednisone—multiple sclerosis	0.000219	0.000482	CcSEcCtD
Cevimeline—Infection—Triamcinolone—multiple sclerosis	0.000219	0.000482	CcSEcCtD
Cevimeline—Infection—Methylprednisolone—multiple sclerosis	0.000219	0.000481	CcSEcCtD
Cevimeline—Haematuria—Methotrexate—multiple sclerosis	0.000218	0.000479	CcSEcCtD
Cevimeline—Shock—Triamcinolone—multiple sclerosis	0.000217	0.000477	CcSEcCtD
Cevimeline—Insomnia—Prednisolone—multiple sclerosis	0.000217	0.000477	CcSEcCtD
Cevimeline—Alopecia—Prednisone—multiple sclerosis	0.000217	0.000476	CcSEcCtD
Cevimeline—Shock—Methylprednisolone—multiple sclerosis	0.000217	0.000476	CcSEcCtD
Cevimeline—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000216	0.000474	CcSEcCtD
Cevimeline—Loss of consciousness—Betamethasone—multiple sclerosis	0.000216	0.000474	CcSEcCtD
Cevimeline—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000216	0.000474	CcSEcCtD
Cevimeline—Epistaxis—Methotrexate—multiple sclerosis	0.000216	0.000473	CcSEcCtD
Cevimeline—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000216	0.000473	CcSEcCtD
Cevimeline—Paraesthesia—Prednisolone—multiple sclerosis	0.000216	0.000473	CcSEcCtD
Cevimeline—Tachycardia—Triamcinolone—multiple sclerosis	0.000215	0.000473	CcSEcCtD
Cevimeline—Nausea—Azathioprine—multiple sclerosis	0.000215	0.000472	CcSEcCtD
Cevimeline—Tachycardia—Methylprednisolone—multiple sclerosis	0.000215	0.000472	CcSEcCtD
Cevimeline—Skin disorder—Methylprednisolone—multiple sclerosis	0.000214	0.00047	CcSEcCtD
Cevimeline—Malnutrition—Prednisone—multiple sclerosis	0.000214	0.000469	CcSEcCtD
Cevimeline—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000213	0.000469	CcSEcCtD
Cevimeline—Agranulocytosis—Methotrexate—multiple sclerosis	0.000213	0.000468	CcSEcCtD
Cevimeline—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000213	0.000468	CcSEcCtD
Cevimeline—Convulsion—Dexamethasone—multiple sclerosis	0.000213	0.000467	CcSEcCtD
Cevimeline—Convulsion—Betamethasone—multiple sclerosis	0.000213	0.000467	CcSEcCtD
Cevimeline—Hypertension—Betamethasone—multiple sclerosis	0.000212	0.000465	CcSEcCtD
Cevimeline—Hypertension—Dexamethasone—multiple sclerosis	0.000212	0.000465	CcSEcCtD
Cevimeline—Asthenia—Mitoxantrone—multiple sclerosis	0.00021	0.000461	CcSEcCtD
Cevimeline—Myalgia—Betamethasone—multiple sclerosis	0.000209	0.000459	CcSEcCtD
Cevimeline—Myalgia—Dexamethasone—multiple sclerosis	0.000209	0.000459	CcSEcCtD
Cevimeline—Anxiety—Dexamethasone—multiple sclerosis	0.000208	0.000457	CcSEcCtD
Cevimeline—Anxiety—Betamethasone—multiple sclerosis	0.000208	0.000457	CcSEcCtD
Cevimeline—Discomfort—Dexamethasone—multiple sclerosis	0.000206	0.000453	CcSEcCtD
Cevimeline—Discomfort—Betamethasone—multiple sclerosis	0.000206	0.000453	CcSEcCtD
Cevimeline—Haemoglobin—Methotrexate—multiple sclerosis	0.000206	0.000453	CcSEcCtD
Cevimeline—Hypotension—Methylprednisolone—multiple sclerosis	0.000206	0.000452	CcSEcCtD
Cevimeline—Pain—Prednisolone—multiple sclerosis	0.000205	0.000451	CcSEcCtD
Cevimeline—Haemorrhage—Methotrexate—multiple sclerosis	0.000205	0.000451	CcSEcCtD
Cevimeline—Pharyngitis—Methotrexate—multiple sclerosis	0.000204	0.000447	CcSEcCtD
Cevimeline—Urethral disorder—Methotrexate—multiple sclerosis	0.000201	0.000442	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000201	0.000442	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000201	0.000441	CcSEcCtD
Cevimeline—Oedema—Dexamethasone—multiple sclerosis	0.0002	0.00044	CcSEcCtD
Cevimeline—Oedema—Betamethasone—multiple sclerosis	0.0002	0.00044	CcSEcCtD
Cevimeline—Diarrhoea—Mitoxantrone—multiple sclerosis	0.0002	0.00044	CcSEcCtD
Cevimeline—Insomnia—Triamcinolone—multiple sclerosis	0.0002	0.000438	CcSEcCtD
Cevimeline—Insomnia—Methylprednisolone—multiple sclerosis	0.000199	0.000438	CcSEcCtD
Cevimeline—Infection—Dexamethasone—multiple sclerosis	0.000199	0.000437	CcSEcCtD
Cevimeline—Infection—Betamethasone—multiple sclerosis	0.000199	0.000437	CcSEcCtD
Cevimeline—Ill-defined disorder—Prednisone—multiple sclerosis	0.000198	0.000436	CcSEcCtD
Cevimeline—Paraesthesia—Triamcinolone—multiple sclerosis	0.000198	0.000435	CcSEcCtD
Cevimeline—Feeling abnormal—Prednisolone—multiple sclerosis	0.000198	0.000434	CcSEcCtD
Cevimeline—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000198	0.000434	CcSEcCtD
Cevimeline—Visual impairment—Methotrexate—multiple sclerosis	0.000198	0.000434	CcSEcCtD
Cevimeline—Anaemia—Prednisone—multiple sclerosis	0.000198	0.000434	CcSEcCtD
Cevimeline—Shock—Dexamethasone—multiple sclerosis	0.000197	0.000433	CcSEcCtD
Cevimeline—Shock—Betamethasone—multiple sclerosis	0.000197	0.000433	CcSEcCtD
Cevimeline—Dyspnoea—Triamcinolone—multiple sclerosis	0.000197	0.000432	CcSEcCtD
Cevimeline—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000196	0.000431	CcSEcCtD
Cevimeline—Nervous system disorder—Betamethasone—multiple sclerosis	0.000196	0.000431	CcSEcCtD
Cevimeline—Agitation—Prednisone—multiple sclerosis	0.000196	0.000431	CcSEcCtD
Cevimeline—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000196	0.000431	CcSEcCtD
Cevimeline—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000196	0.000431	CcSEcCtD
Cevimeline—Tachycardia—Betamethasone—multiple sclerosis	0.000196	0.000429	CcSEcCtD
Cevimeline—Tachycardia—Dexamethasone—multiple sclerosis	0.000196	0.000429	CcSEcCtD
Cevimeline—Dyspepsia—Triamcinolone—multiple sclerosis	0.000194	0.000427	CcSEcCtD
Cevimeline—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000194	0.000426	CcSEcCtD
Cevimeline—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000194	0.000425	CcSEcCtD
Cevimeline—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000194	0.000425	CcSEcCtD
Cevimeline—Malaise—Prednisone—multiple sclerosis	0.000193	0.000423	CcSEcCtD
Cevimeline—Vertigo—Prednisone—multiple sclerosis	0.000192	0.000422	CcSEcCtD
Cevimeline—Eye disorder—Methotrexate—multiple sclerosis	0.000192	0.000421	CcSEcCtD
Cevimeline—Syncope—Prednisone—multiple sclerosis	0.000192	0.000421	CcSEcCtD
Cevimeline—Tinnitus—Methotrexate—multiple sclerosis	0.000191	0.00042	CcSEcCtD
Cevimeline—Anorexia—Dexamethasone—multiple sclerosis	0.000191	0.000419	CcSEcCtD
Cevimeline—Anorexia—Betamethasone—multiple sclerosis	0.000191	0.000419	CcSEcCtD
Cevimeline—Urticaria—Prednisolone—multiple sclerosis	0.000191	0.000419	CcSEcCtD
Cevimeline—Cardiac disorder—Methotrexate—multiple sclerosis	0.00019	0.000418	CcSEcCtD
Cevimeline—Fatigue—Triamcinolone—multiple sclerosis	0.00019	0.000418	CcSEcCtD
Cevimeline—Fatigue—Methylprednisolone—multiple sclerosis	0.00019	0.000417	CcSEcCtD
Cevimeline—Pain—Triamcinolone—multiple sclerosis	0.000189	0.000415	CcSEcCtD
Cevimeline—Loss of consciousness—Prednisone—multiple sclerosis	0.000188	0.000413	CcSEcCtD
Cevimeline—Hypotension—Dexamethasone—multiple sclerosis	0.000187	0.000411	CcSEcCtD
Cevimeline—Hypotension—Betamethasone—multiple sclerosis	0.000187	0.000411	CcSEcCtD
Cevimeline—Angiopathy—Methotrexate—multiple sclerosis	0.000186	0.000409	CcSEcCtD
Cevimeline—Vomiting—Mitoxantrone—multiple sclerosis	0.000186	0.000409	CcSEcCtD
Cevimeline—Convulsion—Prednisone—multiple sclerosis	0.000185	0.000407	CcSEcCtD
Cevimeline—Hypertension—Prednisone—multiple sclerosis	0.000185	0.000405	CcSEcCtD
Cevimeline—Rash—Mitoxantrone—multiple sclerosis	0.000185	0.000405	CcSEcCtD
Cevimeline—Dermatitis—Mitoxantrone—multiple sclerosis	0.000184	0.000405	CcSEcCtD
Cevimeline—Chills—Methotrexate—multiple sclerosis	0.000184	0.000404	CcSEcCtD
Cevimeline—Headache—Mitoxantrone—multiple sclerosis	0.000183	0.000403	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000183	0.000401	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000183	0.000401	CcSEcCtD
Cevimeline—Arthralgia—Prednisone—multiple sclerosis	0.000182	0.0004	CcSEcCtD
Cevimeline—Myalgia—Prednisone—multiple sclerosis	0.000182	0.0004	CcSEcCtD
Cevimeline—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000182	0.0004	CcSEcCtD
Cevimeline—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000182	0.000399	CcSEcCtD
Cevimeline—Anxiety—Prednisone—multiple sclerosis	0.000181	0.000398	CcSEcCtD
Cevimeline—Alopecia—Methotrexate—multiple sclerosis	0.000181	0.000398	CcSEcCtD
Cevimeline—Insomnia—Dexamethasone—multiple sclerosis	0.000181	0.000398	CcSEcCtD
Cevimeline—Insomnia—Betamethasone—multiple sclerosis	0.000181	0.000398	CcSEcCtD
Cevimeline—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00018	0.000396	CcSEcCtD
Cevimeline—Paraesthesia—Betamethasone—multiple sclerosis	0.00018	0.000395	CcSEcCtD
Cevimeline—Paraesthesia—Dexamethasone—multiple sclerosis	0.00018	0.000395	CcSEcCtD
Cevimeline—Discomfort—Prednisone—multiple sclerosis	0.00018	0.000395	CcSEcCtD
Cevimeline—Malnutrition—Methotrexate—multiple sclerosis	0.000179	0.000392	CcSEcCtD
Cevimeline—Hypersensitivity—Prednisolone—multiple sclerosis	0.000177	0.000388	CcSEcCtD
Cevimeline—Dyspepsia—Betamethasone—multiple sclerosis	0.000176	0.000387	CcSEcCtD
Cevimeline—Dyspepsia—Dexamethasone—multiple sclerosis	0.000176	0.000387	CcSEcCtD
Cevimeline—Urticaria—Triamcinolone—multiple sclerosis	0.000175	0.000385	CcSEcCtD
Cevimeline—Urticaria—Methylprednisolone—multiple sclerosis	0.000175	0.000384	CcSEcCtD
Cevimeline—Dysgeusia—Methotrexate—multiple sclerosis	0.000175	0.000384	CcSEcCtD
Cevimeline—Body temperature increased—Triamcinolone—multiple sclerosis	0.000175	0.000383	CcSEcCtD
Cevimeline—Oedema—Prednisone—multiple sclerosis	0.000174	0.000383	CcSEcCtD
Cevimeline—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000174	0.000382	CcSEcCtD
Cevimeline—Decreased appetite—Dexamethasone—multiple sclerosis	0.000174	0.000382	CcSEcCtD
Cevimeline—Decreased appetite—Betamethasone—multiple sclerosis	0.000174	0.000382	CcSEcCtD
Cevimeline—Nausea—Mitoxantrone—multiple sclerosis	0.000174	0.000382	CcSEcCtD
Cevimeline—Infection—Prednisone—multiple sclerosis	0.000173	0.000381	CcSEcCtD
Cevimeline—Back pain—Methotrexate—multiple sclerosis	0.000173	0.000379	CcSEcCtD
Cevimeline—Fatigue—Dexamethasone—multiple sclerosis	0.000173	0.000379	CcSEcCtD
Cevimeline—Fatigue—Betamethasone—multiple sclerosis	0.000173	0.000379	CcSEcCtD
Cevimeline—Shock—Prednisone—multiple sclerosis	0.000172	0.000377	CcSEcCtD
Cevimeline—Pain—Dexamethasone—multiple sclerosis	0.000171	0.000376	CcSEcCtD
Cevimeline—Pain—Betamethasone—multiple sclerosis	0.000171	0.000376	CcSEcCtD
Cevimeline—Nervous system disorder—Prednisone—multiple sclerosis	0.000171	0.000376	CcSEcCtD
Cevimeline—Tachycardia—Prednisone—multiple sclerosis	0.00017	0.000374	CcSEcCtD
Cevimeline—Skin disorder—Prednisone—multiple sclerosis	0.000169	0.000372	CcSEcCtD
Cevimeline—Hyperhidrosis—Prednisone—multiple sclerosis	0.000169	0.00037	CcSEcCtD
Cevimeline—Anorexia—Prednisone—multiple sclerosis	0.000166	0.000365	CcSEcCtD
Cevimeline—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000166	0.000364	CcSEcCtD
Cevimeline—Anaemia—Methotrexate—multiple sclerosis	0.000165	0.000363	CcSEcCtD
Cevimeline—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000165	0.000363	CcSEcCtD
Cevimeline—Feeling abnormal—Betamethasone—multiple sclerosis	0.000165	0.000363	CcSEcCtD
Cevimeline—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000164	0.00036	CcSEcCtD
Cevimeline—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000164	0.00036	CcSEcCtD
Cevimeline—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000163	0.000357	CcSEcCtD
Cevimeline—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000162	0.000356	CcSEcCtD
Cevimeline—Malaise—Methotrexate—multiple sclerosis	0.000161	0.000354	CcSEcCtD
Cevimeline—Vertigo—Methotrexate—multiple sclerosis	0.000161	0.000352	CcSEcCtD
Cevimeline—Leukopenia—Methotrexate—multiple sclerosis	0.00016	0.000351	CcSEcCtD
Cevimeline—Urticaria—Dexamethasone—multiple sclerosis	0.000159	0.000349	CcSEcCtD
Cevimeline—Urticaria—Betamethasone—multiple sclerosis	0.000159	0.000349	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000159	0.000349	CcSEcCtD
Cevimeline—Dizziness—Prednisolone—multiple sclerosis	0.000159	0.000349	CcSEcCtD
Cevimeline—Asthenia—Triamcinolone—multiple sclerosis	0.000158	0.000348	CcSEcCtD
Cevimeline—Abdominal pain—Dexamethasone—multiple sclerosis	0.000158	0.000348	CcSEcCtD
Cevimeline—Abdominal pain—Betamethasone—multiple sclerosis	0.000158	0.000348	CcSEcCtD
Cevimeline—Body temperature increased—Betamethasone—multiple sclerosis	0.000158	0.000348	CcSEcCtD
Cevimeline—Body temperature increased—Dexamethasone—multiple sclerosis	0.000158	0.000348	CcSEcCtD
Cevimeline—Asthenia—Methylprednisolone—multiple sclerosis	0.000158	0.000347	CcSEcCtD
Cevimeline—Insomnia—Prednisone—multiple sclerosis	0.000158	0.000346	CcSEcCtD
Cevimeline—Paraesthesia—Prednisone—multiple sclerosis	0.000157	0.000344	CcSEcCtD
Cevimeline—Pruritus—Triamcinolone—multiple sclerosis	0.000156	0.000343	CcSEcCtD
Cevimeline—Cough—Methotrexate—multiple sclerosis	0.000156	0.000342	CcSEcCtD
Cevimeline—Pruritus—Methylprednisolone—multiple sclerosis	0.000156	0.000342	CcSEcCtD
Cevimeline—Convulsion—Methotrexate—multiple sclerosis	0.000155	0.00034	CcSEcCtD
Cevimeline—Dyspepsia—Prednisone—multiple sclerosis	0.000154	0.000337	CcSEcCtD
Cevimeline—Arthralgia—Methotrexate—multiple sclerosis	0.000152	0.000334	CcSEcCtD
Cevimeline—Myalgia—Methotrexate—multiple sclerosis	0.000152	0.000334	CcSEcCtD
Cevimeline—Chest pain—Methotrexate—multiple sclerosis	0.000152	0.000334	CcSEcCtD
Cevimeline—Decreased appetite—Prednisone—multiple sclerosis	0.000152	0.000333	CcSEcCtD
Cevimeline—Rash—Prednisolone—multiple sclerosis	0.000151	0.000332	CcSEcCtD
Cevimeline—Dermatitis—Prednisolone—multiple sclerosis	0.000151	0.000332	CcSEcCtD
Cevimeline—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000151	0.000331	CcSEcCtD
Cevimeline—Fatigue—Prednisone—multiple sclerosis	0.00015	0.00033	CcSEcCtD
Cevimeline—Headache—Prednisolone—multiple sclerosis	0.00015	0.00033	CcSEcCtD
Cevimeline—Discomfort—Methotrexate—multiple sclerosis	0.00015	0.00033	CcSEcCtD
Cevimeline—Constipation—Prednisone—multiple sclerosis	0.000149	0.000328	CcSEcCtD
Cevimeline—Confusional state—Methotrexate—multiple sclerosis	0.000147	0.000323	CcSEcCtD
Cevimeline—Dizziness—Triamcinolone—multiple sclerosis	0.000146	0.000321	CcSEcCtD
Cevimeline—Dizziness—Methylprednisolone—multiple sclerosis	0.000146	0.00032	CcSEcCtD
Cevimeline—Infection—Methotrexate—multiple sclerosis	0.000145	0.000318	CcSEcCtD
Cevimeline—Feeling abnormal—Prednisone—multiple sclerosis	0.000144	0.000316	CcSEcCtD
Cevimeline—Asthenia—Betamethasone—multiple sclerosis	0.000144	0.000316	CcSEcCtD
Cevimeline—Asthenia—Dexamethasone—multiple sclerosis	0.000144	0.000316	CcSEcCtD
Cevimeline—Nervous system disorder—Methotrexate—multiple sclerosis	0.000143	0.000314	CcSEcCtD
Cevimeline—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000143	0.000313	CcSEcCtD
Cevimeline—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000143	0.000313	CcSEcCtD
Cevimeline—Nausea—Prednisolone—multiple sclerosis	0.000143	0.000313	CcSEcCtD
Cevimeline—Pruritus—Betamethasone—multiple sclerosis	0.000142	0.000311	CcSEcCtD
Cevimeline—Pruritus—Dexamethasone—multiple sclerosis	0.000142	0.000311	CcSEcCtD
Cevimeline—Skin disorder—Methotrexate—multiple sclerosis	0.000142	0.000311	CcSEcCtD
Cevimeline—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000141	0.00031	CcSEcCtD
Cevimeline—Vomiting—Triamcinolone—multiple sclerosis	0.00014	0.000308	CcSEcCtD
Cevimeline—Vomiting—Methylprednisolone—multiple sclerosis	0.00014	0.000308	CcSEcCtD
Cevimeline—Rash—Triamcinolone—multiple sclerosis	0.000139	0.000306	CcSEcCtD
Cevimeline—Dermatitis—Triamcinolone—multiple sclerosis	0.000139	0.000305	CcSEcCtD
Cevimeline—Anorexia—Methotrexate—multiple sclerosis	0.000139	0.000305	CcSEcCtD
Cevimeline—Rash—Methylprednisolone—multiple sclerosis	0.000139	0.000305	CcSEcCtD
Cevimeline—Dermatitis—Methylprednisolone—multiple sclerosis	0.000139	0.000305	CcSEcCtD
Cevimeline—Urticaria—Prednisone—multiple sclerosis	0.000139	0.000304	CcSEcCtD
Cevimeline—Headache—Triamcinolone—multiple sclerosis	0.000138	0.000304	CcSEcCtD
Cevimeline—Headache—Methylprednisolone—multiple sclerosis	0.000138	0.000303	CcSEcCtD
Cevimeline—Abdominal pain—Prednisone—multiple sclerosis	0.000138	0.000303	CcSEcCtD
Cevimeline—Body temperature increased—Prednisone—multiple sclerosis	0.000138	0.000303	CcSEcCtD
Cevimeline—Diarrhoea—Dexamethasone—multiple sclerosis	0.000137	0.000301	CcSEcCtD
Cevimeline—Diarrhoea—Betamethasone—multiple sclerosis	0.000137	0.000301	CcSEcCtD
Cevimeline—Hypotension—Methotrexate—multiple sclerosis	0.000136	0.000299	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000133	0.000292	CcSEcCtD
Cevimeline—Dizziness—Dexamethasone—multiple sclerosis	0.000132	0.000291	CcSEcCtD
Cevimeline—Dizziness—Betamethasone—multiple sclerosis	0.000132	0.000291	CcSEcCtD
Cevimeline—Insomnia—Methotrexate—multiple sclerosis	0.000132	0.00029	CcSEcCtD
Cevimeline—Nausea—Triamcinolone—multiple sclerosis	0.000131	0.000288	CcSEcCtD
Cevimeline—Paraesthesia—Methotrexate—multiple sclerosis	0.000131	0.000287	CcSEcCtD
Cevimeline—Nausea—Methylprednisolone—multiple sclerosis	0.000131	0.000287	CcSEcCtD
Cevimeline—Dyspnoea—Methotrexate—multiple sclerosis	0.00013	0.000285	CcSEcCtD
Cevimeline—Somnolence—Methotrexate—multiple sclerosis	0.00013	0.000285	CcSEcCtD
Cevimeline—Hypersensitivity—Prednisone—multiple sclerosis	0.000129	0.000282	CcSEcCtD
Cevimeline—Dyspepsia—Methotrexate—multiple sclerosis	0.000128	0.000282	CcSEcCtD
Cevimeline—Vomiting—Dexamethasone—multiple sclerosis	0.000127	0.00028	CcSEcCtD
Cevimeline—Vomiting—Betamethasone—multiple sclerosis	0.000127	0.00028	CcSEcCtD
Cevimeline—Decreased appetite—Methotrexate—multiple sclerosis	0.000127	0.000278	CcSEcCtD
Cevimeline—Rash—Betamethasone—multiple sclerosis	0.000126	0.000277	CcSEcCtD
Cevimeline—Rash—Dexamethasone—multiple sclerosis	0.000126	0.000277	CcSEcCtD
Cevimeline—Dermatitis—Betamethasone—multiple sclerosis	0.000126	0.000277	CcSEcCtD
Cevimeline—Dermatitis—Dexamethasone—multiple sclerosis	0.000126	0.000277	CcSEcCtD
Cevimeline—Fatigue—Methotrexate—multiple sclerosis	0.000126	0.000276	CcSEcCtD
Cevimeline—Headache—Betamethasone—multiple sclerosis	0.000126	0.000276	CcSEcCtD
Cevimeline—Headache—Dexamethasone—multiple sclerosis	0.000126	0.000276	CcSEcCtD
Cevimeline—Asthenia—Prednisone—multiple sclerosis	0.000125	0.000275	CcSEcCtD
Cevimeline—Pain—Methotrexate—multiple sclerosis	0.000125	0.000274	CcSEcCtD
Cevimeline—Pruritus—Prednisone—multiple sclerosis	0.000123	0.000271	CcSEcCtD
Cevimeline—Feeling abnormal—Methotrexate—multiple sclerosis	0.00012	0.000264	CcSEcCtD
Cevimeline—Diarrhoea—Prednisone—multiple sclerosis	0.000119	0.000262	CcSEcCtD
Cevimeline—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000119	0.000262	CcSEcCtD
Cevimeline—Nausea—Dexamethasone—multiple sclerosis	0.000119	0.000261	CcSEcCtD
Cevimeline—Nausea—Betamethasone—multiple sclerosis	0.000119	0.000261	CcSEcCtD
Cevimeline—Urticaria—Methotrexate—multiple sclerosis	0.000116	0.000254	CcSEcCtD
Cevimeline—Dizziness—Prednisone—multiple sclerosis	0.000115	0.000253	CcSEcCtD
Cevimeline—Abdominal pain—Methotrexate—multiple sclerosis	0.000115	0.000253	CcSEcCtD
Cevimeline—Body temperature increased—Methotrexate—multiple sclerosis	0.000115	0.000253	CcSEcCtD
Cevimeline—Vomiting—Prednisone—multiple sclerosis	0.000111	0.000244	CcSEcCtD
Cevimeline—Rash—Prednisone—multiple sclerosis	0.00011	0.000242	CcSEcCtD
Cevimeline—Dermatitis—Prednisone—multiple sclerosis	0.00011	0.000241	CcSEcCtD
Cevimeline—Headache—Prednisone—multiple sclerosis	0.000109	0.00024	CcSEcCtD
Cevimeline—Hypersensitivity—Methotrexate—multiple sclerosis	0.000107	0.000236	CcSEcCtD
Cevimeline—Asthenia—Methotrexate—multiple sclerosis	0.000105	0.00023	CcSEcCtD
Cevimeline—Nausea—Prednisone—multiple sclerosis	0.000104	0.000228	CcSEcCtD
Cevimeline—Pruritus—Methotrexate—multiple sclerosis	0.000103	0.000227	CcSEcCtD
Cevimeline—Diarrhoea—Methotrexate—multiple sclerosis	9.98e-05	0.000219	CcSEcCtD
Cevimeline—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	9.85e-05	0.00444	CbGpPWpGaD
Cevimeline—Dizziness—Methotrexate—multiple sclerosis	9.64e-05	0.000212	CcSEcCtD
Cevimeline—CHRM1—GPCR ligand binding—S1PR1—multiple sclerosis	9.36e-05	0.00422	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—S1PR1—multiple sclerosis	9.33e-05	0.0042	CbGpPWpGaD
Cevimeline—Vomiting—Methotrexate—multiple sclerosis	9.27e-05	0.000204	CcSEcCtD
Cevimeline—Rash—Methotrexate—multiple sclerosis	9.19e-05	0.000202	CcSEcCtD
Cevimeline—Dermatitis—Methotrexate—multiple sclerosis	9.18e-05	0.000202	CcSEcCtD
Cevimeline—Headache—Methotrexate—multiple sclerosis	9.13e-05	0.000201	CcSEcCtD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	9.06e-05	0.00408	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	9.06e-05	0.00408	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	9.04e-05	0.00407	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	9.04e-05	0.00407	CbGpPWpGaD
Cevimeline—Nausea—Methotrexate—multiple sclerosis	8.66e-05	0.00019	CcSEcCtD
Cevimeline—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	8.23e-05	0.00371	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	8.23e-05	0.00371	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.11e-05	0.00366	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.11e-05	0.00366	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—GPR65—multiple sclerosis	7.55e-05	0.0034	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—GPR65—multiple sclerosis	7.52e-05	0.00339	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	7.26e-05	0.00327	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	7.23e-05	0.00326	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	7.01e-05	0.00316	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	6.99e-05	0.00315	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CCR1—multiple sclerosis	6.9e-05	0.00311	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CXCL13—multiple sclerosis	6.9e-05	0.00311	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CCR1—multiple sclerosis	6.88e-05	0.0031	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CXCL13—multiple sclerosis	6.88e-05	0.0031	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	6.82e-05	0.00307	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	6.8e-05	0.00306	CbGpPWpGaD
Cevimeline—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.57e-05	0.00296	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	6.46e-05	0.00291	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	6.44e-05	0.0029	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—BCHE—multiple sclerosis	6.3e-05	0.00284	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	6.29e-05	0.00283	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	6.27e-05	0.00283	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	6.22e-05	0.0028	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	6.2e-05	0.00279	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	6e-05	0.0027	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	5.99e-05	0.0027	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	5.84e-05	0.00263	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	5.82e-05	0.00262	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	5.39e-05	0.00243	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	5.37e-05	0.00242	CbGpPWpGaD
Cevimeline—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.33e-05	0.0024	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—FAS—multiple sclerosis	5.32e-05	0.0024	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—S1PR1—multiple sclerosis	5.29e-05	0.00238	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—S1PR1—multiple sclerosis	5.27e-05	0.00238	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—SRM—multiple sclerosis	5.11e-05	0.0023	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CCL3—multiple sclerosis	4.92e-05	0.00222	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CCL3—multiple sclerosis	4.9e-05	0.00221	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	4.85e-05	0.00219	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	4.84e-05	0.00218	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—S1PR1—multiple sclerosis	4.81e-05	0.00216	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—S1PR1—multiple sclerosis	4.79e-05	0.00216	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—PTGER4—multiple sclerosis	4.73e-05	0.00213	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—PTGER4—multiple sclerosis	4.72e-05	0.00213	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CXCR3—multiple sclerosis	4.57e-05	0.00206	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CXCR3—multiple sclerosis	4.56e-05	0.00205	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—RGS1—multiple sclerosis	4.5e-05	0.00203	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—RGS1—multiple sclerosis	4.48e-05	0.00202	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CCR2—multiple sclerosis	4.45e-05	0.002	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CCR2—multiple sclerosis	4.43e-05	0.002	CbGpPWpGaD
Cevimeline—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	4.39e-05	0.00198	CbGpPWpGaD
Cevimeline—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	4.38e-05	0.00197	CbGpPWpGaD
Cevimeline—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.3e-05	0.00194	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—GPR65—multiple sclerosis	4.27e-05	0.00192	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—GPR65—multiple sclerosis	4.25e-05	0.00192	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	4.18e-05	0.00188	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	4.16e-05	0.00188	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CNR1—multiple sclerosis	4.11e-05	0.00185	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CNR1—multiple sclerosis	4.09e-05	0.00184	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—RGS1—multiple sclerosis	4.09e-05	0.00184	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—RGS1—multiple sclerosis	4.07e-05	0.00183	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CCR1—multiple sclerosis	3.9e-05	0.00176	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CXCL13—multiple sclerosis	3.9e-05	0.00176	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CCR1—multiple sclerosis	3.89e-05	0.00175	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CXCL13—multiple sclerosis	3.89e-05	0.00175	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—GPR65—multiple sclerosis	3.87e-05	0.00174	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—GPR65—multiple sclerosis	3.86e-05	0.00174	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—APOE—multiple sclerosis	3.79e-05	0.00171	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	3.76e-05	0.0017	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	3.75e-05	0.00169	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—LINGO1—multiple sclerosis	3.75e-05	0.00169	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—LINGO1—multiple sclerosis	3.73e-05	0.00168	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CXCL10—multiple sclerosis	3.7e-05	0.00167	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CXCL10—multiple sclerosis	3.68e-05	0.00166	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP27B1—multiple sclerosis	3.6e-05	0.00162	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP24A1—multiple sclerosis	3.6e-05	0.00162	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CCR1—multiple sclerosis	3.54e-05	0.0016	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CXCL13—multiple sclerosis	3.54e-05	0.0016	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CXCL13—multiple sclerosis	3.53e-05	0.00159	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CCR1—multiple sclerosis	3.53e-05	0.00159	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	3.53e-05	0.00159	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	3.52e-05	0.00158	CbGpPWpGaD
Cevimeline—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.48e-05	0.00157	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GPC5—multiple sclerosis	3.29e-05	0.00148	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—POMC—multiple sclerosis	3.25e-05	0.00147	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TAGAP—multiple sclerosis	3.25e-05	0.00146	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TAGAP—multiple sclerosis	3.24e-05	0.00146	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CCL5—multiple sclerosis	3.18e-05	0.00143	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CCL5—multiple sclerosis	3.17e-05	0.00143	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SRM—multiple sclerosis	3.05e-05	0.00138	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—MAPK1—multiple sclerosis	3.01e-05	0.00136	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—MAPK1—multiple sclerosis	3e-05	0.00135	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—ALB—multiple sclerosis	2.97e-05	0.00134	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.94e-05	0.00133	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.93e-05	0.00132	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.88e-05	0.0013	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.87e-05	0.00129	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CCR5—multiple sclerosis	2.87e-05	0.00129	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CCR5—multiple sclerosis	2.86e-05	0.00129	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—S1PR1—multiple sclerosis	2.84e-05	0.00128	CbGpPWpGaD
Cevimeline—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.83e-05	0.00128	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—S1PR1—multiple sclerosis	2.83e-05	0.00127	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GPC5—multiple sclerosis	2.76e-05	0.00124	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GPC5—multiple sclerosis	2.75e-05	0.00124	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—RRM1—multiple sclerosis	2.73e-05	0.00123	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PTGER4—multiple sclerosis	2.68e-05	0.00121	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PTGER4—multiple sclerosis	2.67e-05	0.0012	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CXCR3—multiple sclerosis	2.58e-05	0.00116	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CXCR3—multiple sclerosis	2.58e-05	0.00116	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CCL3—multiple sclerosis	2.52e-05	0.00114	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CCL3—multiple sclerosis	2.52e-05	0.00113	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CCR2—multiple sclerosis	2.51e-05	0.00113	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CCR2—multiple sclerosis	2.51e-05	0.00113	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PTGER4—multiple sclerosis	2.43e-05	0.00109	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PTGER4—multiple sclerosis	2.42e-05	0.00109	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RGS1—multiple sclerosis	2.41e-05	0.00109	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RGS1—multiple sclerosis	2.41e-05	0.00108	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CXCR3—multiple sclerosis	2.35e-05	0.00106	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CXCR3—multiple sclerosis	2.34e-05	0.00105	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CNR1—multiple sclerosis	2.32e-05	0.00105	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CNR1—multiple sclerosis	2.31e-05	0.00104	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GPR65—multiple sclerosis	2.29e-05	0.00103	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CCR2—multiple sclerosis	2.28e-05	0.00103	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GPR65—multiple sclerosis	2.28e-05	0.00103	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CCR2—multiple sclerosis	2.28e-05	0.00103	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	2.25e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—POMC—multiple sclerosis	2.24e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	2.24e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—POMC—multiple sclerosis	2.23e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CCL2—multiple sclerosis	2.19e-05	0.000987	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CCL2—multiple sclerosis	2.18e-05	0.000984	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.15e-05	0.000969	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.15e-05	0.000969	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CNR1—multiple sclerosis	2.11e-05	0.000949	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CNR1—multiple sclerosis	2.1e-05	0.000946	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CXCL13—multiple sclerosis	2.09e-05	0.000943	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCR1—multiple sclerosis	2.09e-05	0.000943	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CXCL10—multiple sclerosis	2.09e-05	0.000941	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CXCL13—multiple sclerosis	2.09e-05	0.00094	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCR1—multiple sclerosis	2.09e-05	0.00094	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CXCL10—multiple sclerosis	2.08e-05	0.000938	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SRM—multiple sclerosis	2e-05	0.0009	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.97e-05	0.000887	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CXCL10—multiple sclerosis	1.9e-05	0.000854	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CXCL10—multiple sclerosis	1.89e-05	0.000852	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.85e-05	0.000834	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—IL6—multiple sclerosis	1.82e-05	0.000821	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CCL5—multiple sclerosis	1.8e-05	0.00081	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CCL5—multiple sclerosis	1.79e-05	0.000807	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.73e-05	0.000778	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.72e-05	0.000775	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CCL5—multiple sclerosis	1.63e-05	0.000736	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.63e-05	0.000735	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CCL5—multiple sclerosis	1.63e-05	0.000733	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CCR5—multiple sclerosis	1.62e-05	0.00073	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CCR5—multiple sclerosis	1.61e-05	0.000727	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.6e-05	0.000719	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—IL2RA—multiple sclerosis	1.59e-05	0.000717	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—BCHE—multiple sclerosis	1.57e-05	0.000706	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCL3—multiple sclerosis	1.49e-05	0.000672	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCL3—multiple sclerosis	1.49e-05	0.00067	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CCR5—multiple sclerosis	1.47e-05	0.000663	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CCR5—multiple sclerosis	1.47e-05	0.000661	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL2RA—multiple sclerosis	1.45e-05	0.000653	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL2RA—multiple sclerosis	1.45e-05	0.000651	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTGER4—multiple sclerosis	1.44e-05	0.000647	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTGER4—multiple sclerosis	1.43e-05	0.000645	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PGR—multiple sclerosis	1.41e-05	0.000637	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PGR—multiple sclerosis	1.41e-05	0.000635	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.41e-05	0.000634	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.41e-05	0.000634	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CXCR3—multiple sclerosis	1.39e-05	0.000624	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CXCR3—multiple sclerosis	1.38e-05	0.000622	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CD28—multiple sclerosis	1.37e-05	0.000619	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CD28—multiple sclerosis	1.37e-05	0.000617	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCR2—multiple sclerosis	1.35e-05	0.000607	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCR2—multiple sclerosis	1.34e-05	0.000606	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.29e-05	0.00058	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—POMC—multiple sclerosis	1.27e-05	0.00057	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—POMC—multiple sclerosis	1.26e-05	0.000568	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CNR1—multiple sclerosis	1.24e-05	0.000561	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CNR1—multiple sclerosis	1.24e-05	0.000559	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—POMC—multiple sclerosis	1.15e-05	0.000518	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—POMC—multiple sclerosis	1.15e-05	0.000516	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CCL2—multiple sclerosis	1.12e-05	0.000507	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CCL2—multiple sclerosis	1.12e-05	0.000505	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CXCL10—multiple sclerosis	1.12e-05	0.000505	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CXCL10—multiple sclerosis	1.12e-05	0.000503	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.07e-05	0.00048	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—TYK2—multiple sclerosis	1.02e-05	0.00046	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—TYK2—multiple sclerosis	1.02e-05	0.000459	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CD86—multiple sclerosis	9.8e-06	0.000441	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CD86—multiple sclerosis	9.77e-06	0.00044	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCL5—multiple sclerosis	9.65e-06	0.000435	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCL5—multiple sclerosis	9.61e-06	0.000433	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—APOE—multiple sclerosis	9.42e-06	0.000425	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—BCHE—multiple sclerosis	9.37e-06	0.000422	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—IL2—multiple sclerosis	9.36e-06	0.000422	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—IL2—multiple sclerosis	9.33e-06	0.00042	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SPP1—multiple sclerosis	8.93e-06	0.000402	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SPP1—multiple sclerosis	8.9e-06	0.000401	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCR5—multiple sclerosis	8.69e-06	0.000391	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCR5—multiple sclerosis	8.66e-06	0.00039	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL2RA—multiple sclerosis	8.56e-06	0.000386	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL2RA—multiple sclerosis	8.54e-06	0.000385	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL2—multiple sclerosis	8.5e-06	0.000383	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL2—multiple sclerosis	8.47e-06	0.000382	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—POMC—multiple sclerosis	8.1e-06	0.000365	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—APOE—multiple sclerosis	7.91e-06	0.000356	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—APOE—multiple sclerosis	7.88e-06	0.000355	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALB—multiple sclerosis	7.38e-06	0.000333	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CD80—multiple sclerosis	7.15e-06	0.000322	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CD80—multiple sclerosis	7.12e-06	0.000321	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—POMC—multiple sclerosis	6.79e-06	0.000306	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—POMC—multiple sclerosis	6.77e-06	0.000305	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCL2—multiple sclerosis	6.64e-06	0.000299	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCL2—multiple sclerosis	6.62e-06	0.000298	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—MAPK1—multiple sclerosis	6.5e-06	0.000293	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—MAPK1—multiple sclerosis	6.48e-06	0.000292	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.12e-06	0.000276	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TYK2—multiple sclerosis	6.03e-06	0.000272	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TYK2—multiple sclerosis	6.01e-06	0.000271	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—APOE—multiple sclerosis	5.64e-06	0.000254	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL2—multiple sclerosis	5.02e-06	0.000226	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL2—multiple sclerosis	5e-06	0.000225	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL6—multiple sclerosis	5e-06	0.000225	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL6—multiple sclerosis	4.98e-06	0.000224	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—POMC—multiple sclerosis	4.84e-06	0.000218	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MMP9—multiple sclerosis	4.75e-06	0.000214	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MMP9—multiple sclerosis	4.74e-06	0.000213	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALB—multiple sclerosis	4.41e-06	0.000199	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—STAT3—multiple sclerosis	4.22e-06	0.00019	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—STAT3—multiple sclerosis	4.21e-06	0.00019	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MYC—multiple sclerosis	3.93e-06	0.000177	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TGFB1—multiple sclerosis	3.92e-06	0.000176	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MYC—multiple sclerosis	3.91e-06	0.000176	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TGFB1—multiple sclerosis	3.9e-06	0.000176	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAPK1—multiple sclerosis	3.84e-06	0.000173	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAPK1—multiple sclerosis	3.83e-06	0.000172	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—APOE—multiple sclerosis	3.68e-06	0.000166	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—POMC—multiple sclerosis	3.17e-06	0.000143	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL6—multiple sclerosis	2.95e-06	0.000133	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL6—multiple sclerosis	2.94e-06	0.000133	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALB—multiple sclerosis	2.89e-06	0.00013	CbGpPWpGaD
